TOP TEN perturbations for 39195_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39195_s_at
Selected probe(set): 225862_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39195_s_at (225862_at) across 6674 perturbations tested by GENEVESTIGATOR:
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):-3.722723Number of Samples:2 / 5
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; lung) |
| Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)
Relative Expression (log2-ratio):-2.6983814Number of Samples:2 / 25
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; liver) |
| Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):1.5575666Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)
Relative Expression (log2-ratio):-1.4096832Number of Samples:4 / 2
| Experimental | rectal cancer study 2 (post; chemoradiotherapy) |
| Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. | |
| Control | rectal cancer study 2 (post; no therapy) |
| Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-1.3537102Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)
Relative Expression (log2-ratio):1.3247681Number of Samples:5 / 2
| Experimental | expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS). | |
| Control | expO kidney cancer study 1 (neoplasm, malignant; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm. |
influenza virus study 11 (A/H5N3) / influenza virus study 9 (A/H5N2)
Relative Expression (log2-ratio):-1.2991943Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 9 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. |
Alzheimer's disease study 8 / normal pyramidal neuron (middle temporal gyrus)
Relative Expression (log2-ratio):-1.2549181Number of Samples:15 / 12
| Experimental | Alzheimer's disease study 8 |
| Cortical layer III pyramidal neurons of the middle temporal gyrus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal pyramidal neuron (middle temporal gyrus) |
| Cortical layer III pyramidal neurons of the middle temporal gyrus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |
primitive neuroectodermal tumor study 1 / non-tumor brain tissue
Relative Expression (log2-ratio):-1.2505131Number of Samples:9 / 9
| Experimental | primitive neuroectodermal tumor study 1 |
| Primary tumor tissue sample from the supratentorial brain of pediatric patients with primitive neuroectodermal tumor. | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
expO kidney cancer study 1 (neoplasm, malignant; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):-1.2484751Number of Samples:2 / 4
| Experimental | expO kidney cancer study 1 (neoplasm, malignant; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm. | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |